24.05.2013 • News

Valeant Pharma Near Deal to Acquire Bausch & Lomb

Canada's Valeant Pharmaceuticals International is nearing a deal to acquire eye care company Bausch & Lomb from private equity owner Warburg Pincus for about $9 billion, a person familiar with the matter said on Friday.

The person requested anonymity because the matter is not public. Valeant and Bausch & Lomb could not be immediately reached for comment. Warburg Pincus declined to comment.

The Wall Street Journal, which earlier reported on the talks, said a deal might come as soon as next week.

 

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Virtual Event

High Performance Food Production
Perfection Starts in the Tank

High Performance Food Production

On Demand | Optimize your food production with smarter mixing—join the Ystral seminar to discover 20 real-world applications that cut processing times, reduce costs, and boost product quality.

Top-Feature

most read

Photo
News • Chemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.